Couverture de How This Is Building Me

How This Is Building Me

How This Is Building Me

De : How This Is Building Me
Écouter gratuitement

3 mois pour 0,99 €/mois

Après 3 mois, 9.95 €/mois. Offre soumise à conditions.

À propos de ce contenu audio

 World-renowned oncologist D. Ross Camidge, MD, PhD, sits down with guests to discuss the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences. Science
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • 50: How Biostatistics Expertise Led to a Career of Propelling Ethical Clinical Trial Design: D. Ross Camidge, MD, PhD; and Tom Fleming, PhD

      50: How Biostatistics Expertise Led to a Career of Propelling Ethical Clinical Trial Design: D. Ross Camidge, MD, PhD; and Tom Fleming, PhD
      Dec 24 2025
      How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

      In this episode, Dr Camidge sat down with Tom Fleming, PhD, a professor of biostatistics at the University of Washington School of Public Health in Seattle.

      Drs Camidge and Fleming discussed how Fleming's interest in biostatistics led to a multifaceted career in clinical trial design and analysis. Fleming pursued a PhD in math and statistics and spent his early career learning to bridge quantitative sciences with clinical medicine, working on landmark trials for adjuvant colon cancer and debunking megadoses of Vitamin C as a cancer treatment.

      A primary focus of Fleming’s career was pioneering the use of Data Monitoring Committees (DMCs) in oncology research to safeguard patient interests and trial integrity, later convincing organizations like SWOG to adopt DMCs to prevent premature data releases and biases. He also co-developed the O'Brien-Fleming monitoring boundary, a statistical framework that allows trials to stop early for efficacy only when the signal is undeniably compelling, thereby protecting scientific rigor.

      After moving to the University of Washington, Fleming expanded his focus into infectious diseases. He led international efforts that revolutionized HIV/AIDS prevention, including demonstrating a reduction in heterosexual transmission of the disease through antiretrovirals and significantly reducing mother-to-child transmission in resource-limited settings.

      Fleming remains a staunch advocate for confirmatory trials and the use of overall survival as the "gold standard" end point, often expressing skepticism toward surrogate biomarkers like progression-free survival. In the episode, he emphasized that rigorous science is possible even in the most challenging environments, provided there is a commitment to clinical equipoise and high patient retention. Outside of his professional life, Fleming prioritizes family and coaches youth soccer teams, reflecting his belief in the power of collaboration.
      Afficher plus Afficher moins
      1 h et 11 min
    • 49: How Compelling Communication Makes Early Cancer Detection Part of Everyday Life: With D. Ross Camidge, MD, PhD; and Keith Singer

      49: How Compelling Communication Makes Early Cancer Detection Part of Everyday Life: With D. Ross Camidge, MD, PhD; and Keith Singer
      Dec 10 2025
      How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

      In this episode, Dr Camidge sat down with Keith Singer, the founder and executive director of Catch It In Time.

      Camidge and Singer discussed how Singer's background in broadcasting and cable television has led to a career in promoting cancer awareness. Although Singer initially wanted to be an astronaut, a decline in aerospace engineering jobs during the 1970s and a love for the technical side of high school theater led Singer toward television. He left college early and started his career in Cincinnati, first running a boom microphone and later directing newscasts. Singer explained the career hurdles he faced, noting that they led to opportunities for him to hone his skills and exercise creative freedom.

      In the mid-1980s, a project involving a new pacemaker sparked Singer's interest in using video for health care education. This fascination led him to co-create an innovative platform that broadcast medical programming for physician continuing medical education. Driven by seeing friends and family struggle with cancer, Singer founded the nonprofit Catch It In Time in 2011. His key communication strategy is that cancer should be the supporting actor, not the lead, allowing stories to appeal to targeted audiences based on their hobbies or professions, with cancer awareness as the secondary message.

      Catch It In Time is currently developing The User's Guide to Oncology, a software-based program that uses gaming technology to guide patients with lung cancer, providing essential information to help them have better conversations with their care teams. Singer stressed the importance of short video content for garnering views for this type of content.

      Notably, Catch It In Time recently produced a song titled "Breathe Again" by Lilliana De Los Reyes. "Breathe Again" can be found on all major streaming platforms, and all proceeds are dedicated to cancer awareness and research.
      Afficher plus Afficher moins
      1 h et 4 min
    • 48: How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD

      48: How An Interest in Translational Research and Drug Development Helps Evolve Regulatory Practices: With D. Ross Camidge, MD, PhD; and Gideon Blumenthal, MD
      Nov 26 2025
      How This Is Building Me, hosted by world-renowned oncologist D. Ross Camidge, MD, PhD, is a podcast focused on the highs and lows, ups and downs of all those involved with cancer, cancer medicine, and cancer science across the full spectrum of life’s experiences.

      In this episode, Dr Camidge sat down with Gideon Blumenthal, MD, vice president of Clinical Development Oncology at Merck in Silver Spring, Maryland.

      Drs Camidge and Blumenthal discussed Dr Blumenthal's experience serving on both sides of the oncology regulatory divide. Though initially leaning toward humanities during his education, he pursued a career in medicine. During medical school, he shifted his focus from neuroscience to oncology due to the field’s high unmet need, fascinating drug development pathways, and the intensity of patient interaction. He chose to complete his hematology and oncology fellowship at the National Cancer Institute to immerse himself in translational oncology and drug development.

      Before joining industry, Dr Blumenthal also spent several years working for the FDA. He started there as a medical officer, focusing on all facets of drug development, from ethics and manufacturing to trial design and biostatistics. He emphasized that success at the FDA involves both approving effective agents and identifying drugs that do not work, maintaining transparency through venues like the public Oncologic Drug Advisory Committee meetings. He used FDA data to conduct independent meta-research, such as analyzing the correlation between response rates and overall survival in lung cancer. His proudest achievement at the FDA was helping to establish the Oncology Center of Excellence, which unified drug development reviews across different centers within the agency.

      Dr Blumenthal left the FDA in early 2020, seeking to gain direct experience in developing new therapeutics. Joining Merck, he first worked in regulatory affairs, navigating international regulations in addition to US filing procedures, which are typically prioritized in oncology. He later transitioned into clinical development, and currently focuses on new assets as Merck evolves its pipeline beyond pembrolizumab (Keytruda). Dr Blumenthal concluded that he is excited by the future of oncology, anticipating radical changes driven by new modalities and advanced biomarkers like artificial intelligence–driven digital pathology.
      Afficher plus Afficher moins
      55 min
    Aucun commentaire pour le moment